



Promoting Access to Medical Technologies and Innovation

SECOND EDITION

Intersections between public health, intellectual property and trade

Updated extract: integrated health, trade and IP approach to respond to the COVID-19 pandemic, 30 August 2021

Disclaimer

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion on the part of the World Health Organization (WHO), World Intellectual Property Organization (WIPO) or World Trade Organization (WTO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mentioning of specific companies or products does not imply that they are endorsed or recommended by WHO, WIPO or WTO or preferred to others that are not mentioned. The names of proprietary products are usually distinguished by initial capital letters.

All reasonable precautions have been taken by WHO, WIPO and WTO to veri'y the in'ormation contained in this publication. However, the published material is being distributed without warranty o' any kind, either expressed or implied. The responsibility 'or the interpretation and use o' the material lies with the reader. In no event shall WHO, WIPO and WTO be liable 'or any consequences whatsoever arising 'rom its use.

© World Trade Organization, World Health Organization and World Intellectual Property Organization, 2021

This document is 'reely available 'or redistribution under Creative Commons Attribution - Non Commercial - Share Alike

Contents

Introduction	2
A dramatic impact on health systems and responses at the global level	3
Policy challenges posed by the pandemic	5
Meeting the demand for health technologies and medical services	5
Preserving effective international trade	7
Intellectual property aspects	7
COVID-19 technologies: international initiatives to support R&D and equitable access	10
Regulatory responses	13
Ensuring transparency	14
The way forward	15
Endnotes	16

Introduction

A dramatic impact on health systems and responses at the global level

2019 (CO ID-19)

2019 (

CO ID-19

A . We take the second to Literate H it R & it (IHR) and at CO ID-19 and a . & it is a second to \mathcal{L}_{i} to \mathcal

- 1) R t . . t . IHR . . . t;
- 3) L 💪 🗸 ,
- 4) N t . . t · t . . . t · t ;

6) CO ID-

Policy challenges posed by the pandemic

CO ID-19 ... f ... to the tent of the A that is a section of the section o

 $(\mathcal{A}_{\mathcal{A}}, \mathcal{A}_{\mathcal{A}}, \mathcal{$

Preserving effective international trade

1 200 - 1 0 0 0 0 0 0 0 1 to 0 0 0 to

to to the second to the second

CO ID-19 A . . . t (AC -A) . . t . CO A

.. .. tit tigt ...

to the provide a second of the terms of the to Account that the total and a control of the Account to the Acco Litati Pat Rati (RIP Acara) at the street of

It is a second of the second

...t, tt4 (t // t // / t // t // t // t // t

f ... A + 2021 B ... v. t ... ↓

Regulatory responses

Constant of the first term of

Ensuring transparency

The way forward

- 38 D v A · · · · P · · A · , COVID-19 Global Impact: A World Tour of Competition Law Enforcement (4 "Tracker Maps ♠, 23 J · 2020, -C · tt · C · tt · L & C v · -19, A t N 95551.

- 42 ... t. ... t. ... , C. ... tt. : C. ... t. : C. ... t. ... B.2 ... C. ... t. ... D.2.
- 44 C 11.00 t t 1.00 t t 1.00 t t t ... (1.00 t ... (1.

- D \ A \ P \ A \ COVID-19 Global Impact: A World Tour of Competition Law Enforcement (4 "Tracker Maps ♠, 23 J. 2020, -C tt C tt L & C \ 19 A t N 95551.

- 53 A . . O\ , Supra at 7 49.
- 55 D \ A \ D \ A \ B \ C \ O \ ID-19 G I t A C tt L E t t (4 \ D M ') \(\) 23 J. 2020, -C tt ... C tt L & C \ \ \) -19, A t N 95551.

- 58 A ...t., t. t. ..., t. R .. D ...t. 21 M 2021, v_1 ... t. tt. :// ζ_{i_1} ... v_2 ... v_3 ... v_4

- 101 A\ \cdot \cdot \cdot \tau \cdot \tau \tau \tau \tau \tau \cdot \tau \cdo
- 103 Food and Drugs Act, R.S.C. 1985, c. F-27, s. 37.2.; ... A t ... 31 ... t RIP Ac. ... t
- 104 Food and Drugs Act, R.S.C. 1985, c. F-27, s. 37.2.; Food and Drug Regulations, C.R.C., c. 870, C.07.004.

- 107 CAMD-I N 1 (I), L tt ,
 R 1 P t 1N .IN275967 (7068/DELNP/2010),
 IN319927 (1328/CHENP/2013) IN332280
 (201727012821) t 66 t P t 1 A t
 1970, 1 t tt ://t / ... / ... /CALL%20
 FOR%20RE OCA ION%20OF%20RD %20PA EN %20
 IN%20INDIA.; ... /K , P t tR t
 A t ... O M R t t :
 CO ID-19 P ... O t ... CP 2020,
 1 t tt :// ... C ... C ... /CALL%20
- 109 Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp., N. IPR2019-00554, 2020 L. 4237232 (P. .A.B. J. 23, 2020).
- 111 ... t .

- 132 Av . . t. tt :// / . . . / HA74/ A74 15- . . .

- 137 Av . . . t. tt. :// / . . . / / HA74/A74 . 15- . . .

- 140 Ibid.

- 146 ... t. ... t. ... , P t. t. ... t. t: C t III, ... t. C.5(z).
- 147 Ibid.

- 155 ... ti ://... ... / ... / ... / ... / . ti //... ... / / ... ti //... ... / / / / / / / / / / / / / / / / / / / / / / / / / / ... / ... / ... / ... / ... / ... / / ..

- 158 Av . . . t. tt. :// \forall . . t. \forall /. . . /2020/01/ C -t. t C P2 019- C | 30.01.2020-1. .

- 166 ...t., t. t.,R & t. ... t.t... & : C. t. II, ...t. A.6 .. D.3 ...C. t. I., ...t. A.11.
- 167 ... t , t , t , t , t , HO ... t :C , t I , ... t . A.11.

